Balancing the emerging benefits of AI in pharmacovigilance with new responsibilities and demands from regulators in enhancing ...

Navigating a complex drug development landscape, sponsors must rethink their approach to risk in study design and execution.

In this Q&A, Megan Bailey, EVP and president of central laboratories and international, Labcorp, discusses how central labs ...

In this video interview, Matt Robinson, PhD, senior director, oncology research program, National Comprehensive Cancer ...

In an interview with ACT senior editor Andy Studna at the 2025 DIA Global Annual Meeting, Carie Pierce, SVP, global head of growth & business development, DIA, discusses the growing emphasis on ...

Global R&D leaders discuss the need for collaboration in medical research and how regulatory agencies are working to create the proper environment for advancements.

Joint Clinical Assessment is now a parallel requirement under HTAR. Health technology developers must prepare for a JCA ...

In this video interview, Matt Robinson, PhD, senior director, oncology research program, National Comprehensive Cancer ...

Cross-sector partnership launches EQBMED. Initially funded by PhRMA and established as a cross-sector collaborative, ...

In this video interview, Jim Kremidas, executive director, Association for MultiSite Research Corporations (AMRC), discusses ...

Phase III DeLLphi-304 results show T-cell engager Imdelltra (tarlatamab) delivers superior overall survival, improved ...

Recent analysis explores AI's momentum in drug development, showcasing rapid adoption and significant time savings, despite ...